Tumour marker tests for testicular cancer
Tumour markers are measured from a blood test. They can help diagnose some testicular cancers and show how well treatment is working.
Some testicular cancers make chemicals or proteins called tumour markers. These are released into the blood. Doctors can measure them with simple blood tests.
Not everyone with testicular cancer have raised markers. Most non‑seminomas and some seminomas have raised levels of tumour markers.
We have information about the types of testicular cancer.
Tumour markers can be used to:
- diagnose testicular cancer
- monitor you after surgery
- check how you are responding to treatment
- check that the cancer has not come back.
You will have blood tests to measure tumour markers before surgery to remove the testicle. You will have them tested again usually a week after surgery. Even if you do not have raised tumour markers before surgery, you may still have them checked afterwards.
If the tumour markers fall quickly after the operation, it can be a good sign that all the cancer has been removed. This helps the doctors plan your treatment.
You will get used to having regular blood tests to check the levels of your tumour markers. It’s very important to attend your appointments to have them checked.
There are three main tumour markers:
Alpha–fetoprotein (AFP) can be raised in non-seminomas but not in seminomas.
Human chorionic gonadotrophin (HCG)
Human chorionic gonadotrophin (HCG) can be raised in non-seminomas and sometimes in seminomas.
Lactic dehydrogenase (LDH)
Lactic dehydrogenase (LDH) can be raised in both seminomas and non-seminomas.
Below is a sample of the sources used in our testicular cancer information. If you would like more information about the sources we use, please contact us at firstname.lastname@example.org
European Association of Urology. Guidelines on Cancer. 2016. Available from: www.baus.org.uk/_userfiles/pages/files/professionals/sections/oncology/EAU2015-Testicular-Cancer.pdf (accessed August 2018)
European Society for Medical Oncology, eUpdate. Testicular Seminoma and Non-Seminoma Treatment Recommendations. June 2017. Available from: www.esmo.org/Guidelines/Genitourinary-Cancers/Testicular-Seminoma-and-Non-Seminoma/eUpdate-Treatment-Recommendation (accessed August 2018).
Scottish Intercollegiate Guidelines Network, Management of adult testicular germ cell tumours. Available from: www.sign.ac.uk/sign-124-management-of-adult-testicular-germ-cell-tumours.html (accessed August 2018).
UpToDate. Clinical manifestations, diagnosis, and staging of testicular germ cell tumors. January 2018. Available from: www.uptodate.com/contents/clinical-manifestations-diagnosis-and-staging-of-testicular-germ-cell-tumors (accessed August 2018).
This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer. It has been approved by Senior Medical Editor, Dr Jim Barber, Consultant Clinical Oncologist.
Our cancer information has been awarded the PIF TICK. Created by the Patient Information Forum, this quality mark shows we meet PIF’s 10 criteria for trustworthy health information.
Content under review
The language we use
We want everyone affected by cancer to feel our information is written for them.
We try to make sure our information is as clear as possible. We use plain English, avoid jargon, explain any medical words, use illustrations to explain text, and make sure important points are highlighted clearly.
We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected. Our aims are for our information to be as clear and relevant as possible for everyone.
You can read more about how we produce our information here.